ASND · Ascendis Pharma A/S Ordinary Share
View on chartInsiders & Stakes
| Scott Thomas Smith EVP & Chief Financial Officer | ▲ Buy | Open Market | 4,367 Shares held | 6/2/2026 | View profile |
| HOLTUG LARS | ▼ Sell | Open Market | 4,000 Shares held | 9/2/2026 | View profile |
| Jean Jacques Bienaime Chief Executive Officer | ▲ Buy | Open Market | 2,900 Shares held | 8/14/2026 | View profile |
| Flemming Steen Jensen See Remarks | ▼ Sell | Open Market | 0 Shares held | 5/11/2026 | View profile |
| Bodenhoff Mads SVP & PAO | ▼ Sell | Open Market | 0 Shares held | 9/8/2026 | View profile |
Transaction History
| Bodenhoff Mads | ▲ Buy | Option Exercise | 3,000 | $330K | 9/8/2026 |
| Bodenhoff Mads | ▼ Sell | Open Market | 3,000 | $811K | 9/8/2026 |
| HOLTUG LARS | ▼ Sell | Open Market | 236 | $62K | 9/2/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,100 | $270K | 8/14/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 900 | $222K | 8/14/2026 |
| Scott Thomas Smith | ▲ Buy | Open Market | 100 | $22K | 6/2/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 200 | $45K | 5/29/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 200 | $44K | 5/29/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 100 | $22K | 5/29/2026 |
| Scott Thomas Smith | ▲ Buy | Open Market | 250 | $56K | 5/29/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 200 | $47K | 5/26/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 200 | $48K | 5/26/2026 |
| Flemming Steen Jensen | ▼ Sell | Open Market | 19,460 | $4.6M | 5/11/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Ascendis Pharma signs BioMarin license deal, ends litigation
Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.
Ascendis Pharma signs BioMarin license deal, ends litigation. Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.